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Background: Loss of STAT1 (Signal Transducer and Activator of Transcription-1) has been implicated in the
pathobiology of a number of cancer types. Nonetheless, the biological and clinical significance of STAT1 in
esophageal squamous cell carcinomas (ESCC) has not been comprehensively studied.
Methods: Using immunohistochemistry, we detected the STAT1 expression in a cohort of ESCC patients; In-vitro
experiments, we used enforced gene transfection of STAT1C into two STAT1- weak/negative ESCC cell lines and
siRNA knockdown of STAT1 in two STAT1-strong ESCC cell lines to detect STAT1 function in ESCC.
Results: We found that the expression of STAT1 was heterogeneous in ESCC, with 64 (49.0%) strongly positive
cases, 59 (45.0%) weakly positive cases and 8 (6.1%) negative cases. STAT1 expression inversely correlated with the
depth of tumor invasion and tumor size (p=0.047 and p=0.029, respectively, Chi square). Furthermore, patients with
STAT1-strong/weak tumors had a significantly longer survival compared to those with STAT1-negative tumors (33.6
months versus 13.1 months, p=0.019). In patients carrying tumors of aggressive cytology (n=50), those with STAT1-
strong tumors survived significantly longer than those with STAT1-weak/negative tumors (34.6 months versus 20.5
months, p=0.011). Our in-vitro experiments revealed that STAT1 is proapoptotic and inhibitory to cell-cycle
progression and colony formation. Lastly, we found evidence that STAT1 signaling in ESCC cells down-regulated the
expression and/or activity of NF-κB and STAT3, both of which are known to have oncogenic potential.
Conclusion: To conclude, our findings suggest that STAT1 is a tumor suppressor in ESCC. Loss of STAT1, which is
frequent in ESCC, contributes to the pathogenesis of these tumors.
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Members of the STAT protein family are known to regulate
various cellular processes involved in oncogenesis, includ-
ing cell cycle progression, apoptosis, angiogenesis, invasion,
metastasis, and evasion of the immune system [1]. STAT1,
as the first discovered member of the STAT family, serves
as the principal mediator of both type I and type II inter-
feron activation [2]. Recent studies have revealed that the
expression of STAT1 is frequently lost in various types of
human cancer such as breast cancer, head and neck cancer,
multiple myeloma and leukemia [3]. Furthermore, it has
been reported that STAT1 can inhibit the growth of benign* Correspondence: minsu@stu.edu.cn; rlai@ualberta.ca
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unless otherwise stated.and neoplastic cells by regulating the transcription and ex-
pression of a host of pro-apoptotic and anti-proliferative
genes, such as caspases, BCL-xL and p21waf1 [4]. Overall,
these observations suggest that STAT1 carries tumor sup-
pressor functions.
Esophageal cancer is one of the leading causes of
cancer-related deaths worldwide [5]. This type of cancer
is known to be highly frequent in specific geographic re-
gions in China, such as the Chaoshan area. Specifically,
the annual average age-standardized incidence rate of
esophageal cancer in Chaoshan is 74.5 /100,000 people
[6], as compared to 7.0/100,000 people worldwide. This
finding suggests that various genetic and/or environmen-
tal factors may predispose the population in Chaoshan to
esophageal cancer. Interestingly, esophageal cancer found
in Chaoshan predominantly carries the histology of squa-
mous cell carcinoma, in contrast with that in the WesternLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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carcinoma [7]. The pathogenesis of ESCC is incompletely
understood. The overall survival of these patients remains
to be relatively poor, with the overall 5-year survival rate
being approximately 15% [8]. In one previous study, it was
found that γ-interferon can induce significant apoptosis in
ESCC cell lines and this process correlates with STAT1 ac-
tivation [9]. In parallel with this observation, it was re-
ported that the EGF-STAT1 signaling pathway, which is
active in normal esophageal epithelial cells, is lost in a
considerable fraction of esophageal cancer; furthermore,
loss of EGF-STAT1 signaling was found to correlate with
a worse clinical outcome [10]. Nevertheless, the clinical
and biological significance of STAT1 in ESCC has never
been directly or comprehensively examined.
In the present study, we tested our hypothesis that
STAT1 is a tumor suppressor in ESCC. First, using immu-
nohistochemistry and Western blots, we comprehensively
evaluated the expression of STAT1 in a large cohort of
ESCC harvested from patients from Chaoshan. Second,
we evaluated the clinical and prognostic significance of
STAT1 in ESCC. Third, we used an in-vitro model to
assess the biological functions of STAT1 in ESCC cells.
Methods
ESCC tumor samples and cell lines
We collected 131 consecutive ESCC tumors at the Shantou
Tumor Hospital between 2005 and 2012. All patients
underwent potentially curative surgery without pre-
operative chemotherapy or radiotherapy. In this cohort, 98
were men and 33 were women; the age was 36-78 years,
with a median of 57 years. Follow-up data was available for
74 patients; most (58, 78.4%) died during the follow-up
period (median, 31.4 months). The study was approved by
the ethical review committees of the Medical College of
Shantou University. All participants involved in our study
were given written informed consents.
Four ESCC cell lines (EC1, EC109, KYESE150 and
KYSE510) and 4 human esophageal immortalized epithe-
lial cell lines (SHEE, NE2, NE3, and NE6) were included
in this study. The ESCC cell lines were gifts from Shantou
University Medical College and esophageal immortalized
epithelial cell lines were gifts from University of Hong
Kong. All of them were cultured in DMEM supplemented
with 10% fetal bovine serum at 37°C under 5% CO2.
Antibodies, subcellular fractionation and western blotting
Western blot analysis was performed using standard
techniques as previously described [11]. The following
antibodies were employed: anti-STAT1 (1:1000) and anti-p-
STAT1 (Tyr-701) (1:1000), anti-FLAG (1:1000), anti-caspase
3 (1:1000), anti-survivin (1:1000), anti- BCL-2 (1:1000) anti-
p21 (1:1000) and anti-cyclin D1 (1:1000), all of which were
purchased from Cell Signaling (Danvers, MA, USA). Anti-STAT3 (1:1000), anti-p-STAT3 (Tyr-705) (1:1000), anti-
BCL-xL (1:1000) and anti-ß-actin (1:1000) were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Densitometric analysis was performed using the ImageJ ana-
lysis system (Bethesda, WA, USA); the values for the STAT1
bands were normalized to those of the β-actin bands.
Immunohistochemistry
Immunohistochemistry to detect STAT1 expression was
performed using a method similar to that described pre-
viously [12]. Using the same antibody we employed for
our Western blot studies, we performed immunohisto-
chemistry and the staining results were independently
evaluated by two pathologists who were blinded to the
clinical data. For each case, the percentages of cells
showing negative, weak or strong cytoplasmic STAT1
staining was recorded. Using our scoring system (the
sum of % of cells strongly positive for STAT1 x 3 and %
of cells weakly positive for STAT1 x 1), we determined
that a cut-off of 80 points allowed us to achieve the low-
est p-values in our statistical analysis. Thus, tumors with
a score of <80 point were classified as STAT1-weak
whereas those with a score of ≥80 points were classified
as STAT1-strong.
Co-immunoprecipitation
A total of 2 μg of anti-STAT3 monoclonal antibody (Santa
Cruz Biotechnology) was added to 500 μg of protein lysate
isolated in cell lytic M (Sigma Aldrich, St Louis, MD,
USA) and the samples were rotated overnight at 4°C. Sub-
sequently, 30 μl of protein G Plus/A beads (Emdmillipore,
Billerica, MA, USA) was added to the samples and rocked
overnight at 4°C. The beads were then washed 3 times
with cold phosphate-buffered saline followed by the final
wash using cold cell lysis buffer. Western blot analysis was
then performed using standard techniques as previously
described [11].
Plasmids, cell transfection and NF-κB transcriptional
activity
FLAG-tagged STAT1C cloned into the backbone of
pcDNA3.1 was a gift from Dr. Ouchi (University of New
York) [13]. For each experiment, 1 × 106 ESCC cells
were transiently transfected with 10 μg of STAT1C
vector or the pcDNA3.1 empty vector (Invitrogen, Bur-
lington, Ontario, CA) in 6-well plates using the lipofec-
tamine 2000 reagent (Invitrogen) as per manufacturer’s
suggested protocol. The NF-κB transcriptional activity
analyses were performed as previously described [12].
Short interfering RNA and gene transfection
5 × 106 ESCC cells in 2 ml of culture medium were trans-
fected with 100 pmol of SMARTpool-designed siRNA
against STAT1 obtained from Dharmacon (Lafoyetle, CO,
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con) were used as the negative controls. Gene transfection
was performed by using lipofectamine RNAiMax (Invitro-
gen) as per manufacturer’s suggested protocol.
Cell-cycle analysis by flow cytometry and assessment of
cell growth
Flow cytometry analyses were performed at the University
of Alberta flow cytometry core facility as previously de-
scribed [12]. All experiments were performed in triplicates.
To assess cell growth, ESCC cells were plated at a dens-
ity of 20,000/ml of culture medium. Cell count, done daily
for 4 days, was performed using trypan blue staining
(Sigma-Aldrich) according to the manufacturer’s protocol.
Triplicate experiments were performed.
Colony formation assay
After STAT1C transfection, 500 cells/well were plated in
six-well plates and incubated 10 days at 37°C. The cells
were fixed with 4% buffered formalin for 15 min and
then stained with 1% crystal violet (Sigma Aldrich) for
30 min. The plates were gently washed with PBS and
dried before microscopic evaluation. Cell clusters with
>30 cells were considered as a colony.
Quantitative RT-PCR
Using the RNeasy Mini Kit (QINGEN, Valencia, CA,
USA), total cellular RNA was extracted from cells follow-
ing the manufacture’s protocol. Reverse transcription was
performed using 1 μg of total RNA and superscript re-
verse transcriptase obtained from Invitrogen. Quantitative
PCR was performed using SYBR green (Invitrogen), and
the primer sets for STAT1 and GAPDH were purchased
from Invitrogen. For both primer sets, the PCR conditions
were as follows: 95°C for 10 minutes, followed by 40 cycles
of 95°C for 15 seconds and 60°C for 1 minute. Samples
were processed on an ABI 9700 HT system (Applied Bio-
systems Inc., Foster City, CA). Results were examined
using the SDS 2.2 software, and the relative expression
levels of STAT1 were calculated by normalizing with those
of GAPDH.
Cell invasion assay
The invasion assays were done using basement membrane
(Cell biolabs, NY). The ESCC cell treat with STAT1C or
empty vector were prepared before the experiment. Then,
5 × 105 cells in 300 μL serum-free DMEM supplemented
were seeded into the upper part of each chamber, whereas
the lower compartments were filled with 500 μl of 10%
fetal bovine serum media. Following incubation for
48 hours at 37°C, the insert was incubated in the cell de-
tachment solution. The invasiveness was determined by
fluorescence measurement, and the extent of invasion wasexpressed as an average number of cells per microscopic
field.
Statistical analysis
Statistical analysis was performed with the SPSS15.0
software. The association between expression of STAT1
and survival was analyzed using the Kaplan–Meier’s.
The correlation between STAT1 and other clinical pa-
rameters was evaluated using Chi square or Student’s t
test. A value of p < 0.05 was considered as statistically
significant.
Results
Expression of STAT1 in esophageal squamous cell
carcinoma (ESCC)
To survey the expression of STAT1 expression in our
cohort of ESCC, we performed immunohistochemistry
(IHC) applied to paraffin-embedded tissues. STAT1 im-
munoreactivity, assessed based on the presence of cyto-
plasmic staining, was detectable in the vast majority of
cases (123 of 131, 93.8%). The staining intensity was cat-
egorized as strong (n = 64, 49.0%) or weak (n = 59,
45.0%) (Figure 1). Of these 123 STAT1-positive tumors,
nuclear staining was detectable in 58 (47.2%) cases.
The remaining 8 (6.1%) cases had no detectable cyto-
plasmic or nuclear STAT1 expression. Benign esopha-
geal epithelial cells had relatively strong STAT1
immunostaining in both their nuclei and cytoplasm (il-
lustrated in Figures 1A e and 1A f).
We then validated the IHC findings using Western
blots. Of the 131 cases studied by IHC, fresh tumor tis-
sues were available in 57 cases. STAT1 at 91 kd was de-
tectable in all tumors examined, although the intensity
was variable, as illustrated in Figure 1B. Densitometry
analysis was performed to generate a value for the
STAT1 band derived from each of the 57 cases. Based
on these values, the 57 cases were categorized as
STAT1-high (n = 23, 40.4%) or STAT1-low (n = 34,
59.6%). As shown in Table 1, data generated from the
IHC and Western blot studies significantly correlate
with each other (p = 0.0003, Fisher exact test). Specific-
ally, 19 (33.3%) cases showing strong IHC for STAT1
were STAT1-high by Western blots; 23 (40.4%) cases
showing weak/negative IHC for STAT1 were STAT1-low
by western blots.
The clinical significance of STAT1 expression in ESCC
We then assessed if STAT1 expression detectable by
IHC correlated with various and clinical and pathologic
parameters, including gender, location and size of the
tumor, lymph node metastasis, histologic grade, depth of
tumor invasion and the overall clinical stage. As summa-
rized in Table 2, we found that STAT1 expression in-
versely correlated with the depth of tumor invasion and
Figure 1 (See legend on next page.)
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Figure 1 Heterogeneous STAT1 expression in ESCC. (A) By immunohistochemistry applied to formalin-fixed paraffin-embedded tissues, variable
levels of STAT1 were detectable in most ESCC tumors examined. The staining was predominantly cytoplasmic. Based on the staining intensity, tumors
in our cohort was categorized into STAT1-strong (a) or STAT1-weak (b); 8 cases were STAT1-negative (c) (IHC stain, scale bar, 20 μm). Nuclear staining
of STAT1 was detected in some ESCC cases (d) (IHC stain, scale bar, 50 μm). The normal epithelium (e) from a STAT1-weak tumor (shown in f) was also
illustrated (scale bar, 20 μm). (B) By Western blots, STAT1 expression in ESCC tumors was examined. Compared to the benign esophageal tissue
harvested at the surgical margins in the same specimens (labeled as N) cancerous tissues (labeled as Ca) often expressed a lower level of STAT1. Thus,
tumors from patient #1, 2 and 4 were categorized as STAT1-low. A small subset of tumors (e.g. that from patient #3) were categorized as STAT1-high,
since the expression of STAT1 in the cancerous tissue was appreciably higher than that of the benign esophageal tissues in the same specimen. (C) By
Kaplan-Meier analysis, we found no significant correlation between overall survival and the expression level of STAT1, when the two groups were
defined as STAT1-strong and STAT1-weak/negative (a). In contrast, we found a significant correlation between overall survival and the expression level
of STAT1 protein levels when the two groups were defined as STAT1-positive or STAT1-negative (b). With the subset of patients carrying poorly or
intermediate-differentiated tumors, those with STAT1-strong tumors survived significantly longer than those with STAT1-weak/negative tumors (c).
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square). Cases with strong STAT1 expression also showed
a trend toward a higher degree of histologic differentiation
(p = 0.074, Chi square). Compared to the poorly differenti-
ated tumors (n = 12), well- or intermediate-differentiated
tumors (n = 129) significantly correlated with strong
STAT1 immunostaining (p = 0.032, Fisher square). Nu-
clear expression of STAT1 did not show significant correl-
ation with any of these clinicopathologic parameters.
Clinical follow-up data was available for 74 of the 131
patients included in this study (median follow-up,
31.4 months; range 1-70 months). The survival data was
analyzed using Kaplan-Meier’s. Approximately half of
these tumors (34 of 74, 45.9%) were assessed strongly
positive for STAT1 by IHC, and 40 (54.0%) were
assessed weak/negative. The overall survival of patients
with STAT1-strong tumors was found to be similar to
that of patients with STAT1-weak/negative tumors
(35.9 months versus 31.1 months, p > 0.05). In contrast,
patients with STAT1-strong/weak tumors (n = 66) had a
significantly longer survival compared to those with
STAT1-negative tumors (n = 8) (33.6 months versus
13.1 months, p = 0.019). Furthermore, of the 74 patients
for whom follow-up data was available, 50 carried poorly
or intermediate-differentiated tumors. In this sub-group,
patients with STAT1-strong tumors survived signifi-
cantly longer than those with STAT1-weak/negative tu-
mors (34.6 months versus 20.5 months, p = 0.011).Table 1 STAT1 expression in ESCC: significant correlation






Strong 19 11 30
Weak 4 23 27
negative 0 0 0
Total* 23 34 57 P = 0.0003
*all cases in this cohort were positive for STAT1.Nuclear STAT1 expression again did not significantly
correlate with the overall survival in this sub-group.
Roles of STAT1 in ESCC cell lines
STAT1 expression in ESCC cell lines
In light of the clinical significance of STAT1 in ESCC, we
examined its roles in ESCC using an in-vitro model. The
expression of STAT1 in a cohort of human ESCC cell lines
(EC1, EC109, KYSE150 and KYSE510) as well as a cohort
of human immortalized esophageal epithelial cell lines
(SHEE, NE2, NE3 and NE6) was examined using Western
blots. MCF7, an estrogen receptor-positive breast cancer
cell line, served as the positive control for STAT1. As
shown in Figure 2, we were able to detect STAT1 in 6 of
these 8 cell lines; EC109 and SHEE were STAT1-negative.
In the 6 STAT1-positive cell lines, EC1 and KYSE150
expressed STAT1 relatively weakly, whereas KYSE510,
NE2, NE3 and NE6 expressed STAT1 relatively strongly.
The expression of the phosphorylated/activated form of
STAT1 (p-STAT1) in these cell lines was also assessed in
these 8 cell lines. Except for EC1, all STAT1-positive cell
lines expressed p-STAT1, although all of the immortalized
cell lines (including NE2, NE3 and NE6) expressed p-
STAT1 relatively weakly.
The biological impact of STAT1C in ESCC cell lines
Using the ESCC cell lines, we then performed specific
in-vitro studies. First, we examined the biological im-
pact of enforced expression of the constitutively active
form of STAT1 (i.e. STAT1C) in ESCC. To this end, EC1
and EC109, both of which were STAT1-weak/negative
cell lines, were employed and they were subjected to
gene transfection of STAT1C. As shown in Figure 3A,
the expression of STAT1C was confirmed by the high
intensity of the total STAT1 band and the strong ex-
pression of FLAG, which was tagged to the STAT1C
construct. These changes correlated with a significant
decrease in the number of viable cells, as assessed using
the trypan blue exclusion assay (Figure 3B). As shown
in Figure 3C and D, STAT1C transfection in EC1 and
EC109 cells led to a significant decrease in colony
Table 2 Correlations between STAT1 expression and various clinicopathologic parameters in ESCC
Parameter Case
number
STAT1 expression by IHC Result
Negative/Weak Strong
Age ≤57 66 31 35 p = 0.337
>58 65 36 29
Gender Male 98 49 49 p = 0.653
Female 33 18 15
Tumor site Upper 13 8 5 p = 0.572
Middle 104 51 53
lower 14 8 6
Differentiation Poor 12 10 2 p = 0.074
Intermediate 75 37 38
Well 44 20 22
Tumor size >5 cm 82 48 34 p = 0.029*
<5 cm 49 19 30
Depth of invasion T1-T2 103 48 55 p = 0.047*
T3-T4 28 19 9
Lymph metastasis Yes 68 32 36 p = 0.286
No 63 35 27
Clinical stage 1 6 4 2 p = 0.257
2 55 30 23
3 64 32 32
4 6 1 5
*p<0.05.
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fected with the empty vector (p < 0.001 and p < 0.05 in
both cell lines). As shown in Figure 4A, the occurrence
of apoptosis was supported by the expression of cleaved
caspase 3 in both cell lines. Correlating with these
changes, there was a marked reduction in the expres-
sion levels of several anti-apoptotic proteins including
BCL-2, BCL-xL and survivin. Furthermore, we also ob-
served changes in two proteins known to regulate G1
cell-cycle progression including p21Waf1 and cyclin D1.
Specifically, transfection of STAT1C into EC1 andFigure 2 Expression of STAT1 and phospho-STAT1 in ESCC (n = 4) and
EC1, EC109, KYESE150 and KYSE510 and human esophageal immortalized c
line, served as a positive control. The expression of STAT1 was heterogeneo
generally in parallel with the expression of STAT1.EC109 substantially upregulated p21Waf1, a negative
regulator of G1 cell-cycle progression [14]. Cyclin D1, a
promoter of G1 cell-cycle progression [15], was down-
regulated. Based on the results of the time-course ex-
periment (Figure 4B), the decrease in the cyclin D1
protein level began as early as 6 hours after STAT1C
gene transfection, indicating that the decrease in cyclin
D1 was not due to the apoptotic activity. As shown in
Figure 4C, cell cycle analysis showed a significant in-
crease in the sub-G1 fractions in EC1 and EC109 cells
transfected with STAT1C.esophageal immortalized cell lines (n = 4). ESCC cell lines included
ell lines included SHEE, NE2, NE3 and NE6. MCF7, a breast cancer cell
us among these cell lines, and the expression of phospho-STAT1 was
Figure 3 Gene transfection of STAT1C significantly decreases cell
growth and tumorigenecity in ESCC cell lines. Using Western blot
analysis, the gene transfection of STAT1C in EC1 and EC109 cells was
shown to be effective, since the levels of STAT1, phospho-STAT1 and
FLAG were dramatically increased 2 days after STAT1C transfection (A).
Cell growth, as assessed by trypan blue cell counting, was found to be
significantly decreased after STAT1C transfection in EC1 and EC109 cells
(B) (* p < 0.05). Tumorigenecity, assessed by using colony formation
assay, was significantly lower in EC1 and EC109 cells transfected with
STAT1C, as compared to cells transfected with an empty vector (C) (**
p < 0.001). (D) Transwell invasion assay showed that the transfection of
STAT1C significantly inhibited cell invasion both ESCC cell lines. Results
shown are representative of three independent experiments. (E.V.:
empty vector).
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ESCC cell lines
Next, the biological effects of siRNA knockdown of
STAT1 in ESCC cells were evaluated. KYSE150 and
KYSE510 cells, which showed the highest level of STAT1
expression among the 8 examined cell lines, were treated
with STAT1 siRNA. As shown in Figure 5A and B, STAT1
siRNA induced a dramatic reduction in the STAT1 ex-
pression level in both cell lines. With this experimental
system, we found that siRNA knockdown of STAT1 sig-
nificantly decreased the number of viable cells, which was
assessed by using the trypan blue exclusion assay (p < 0.05
for both cell lines) (Figure 5C). Furthermore, using colony
formation assay, we found that siRNA knockdown of
STAT1 of KYSE150 and KYSE510 induced a significant
decrease in colony formation (p < 0.0001, p < 0.0001, re-
spectively) (Figure 5D). As shown in Figure 5E, Western
blot studies showed changes in the expression of p21waf1,
cyclin D1, BCL-2 and BCL-xL in a pattern opposite to that
seen in EC1 and EC109 cells transfected with STAT1C. As
shown in Figure 5F, cell cycle analysis showed a significant
decrease in the sub-G1 fractions in KYSE150 and
KYSE510 cells transfected with siRNA against STAT1,
compared with the control.
STAT1 inhibits NF-κB
Previous studies have shown that STAT1 can block NF-κB
by downregulating TNF-α [16]. In view of the importance
of NF-κB in the biology of ESCC [17,18], we hypothesized
that the biological effects of STAT1C in ESCC may be me-
diated by down-regulating the NF-κB signaling. In keeping
with this concept, we found that transfection of STAT1C
into EC1 and EC109 cells resulted in a substantial de-
crease in the phosphorylation of NF-κB p65, a marker of
NF-κB activation [19] (Figure 6A). By subcellular fraction-
ation, we also found that STAT1C transfection induced a
dramatic decrease in the nuclear localization of NF-κB
p65 or phospho-NF-κB p65 in both cell lines (Figure 6B).
Lastly, we assessed the transcriptional activity of NF-κB
using a commercially available luciferase reporter construct.
Figure 4 Gene transfection of STAT1C upregulated apoptosis and induced sub-G1 cell cycle increase. By western blots, gene transfection
of STAT1C into ESCC cell lines induced cleavages of caspase 3, downregulated several pro-apoptotic proteins (including BCL-2, BCL-xL, survivin),
and promoted G1 cell-cycle arrest by decreasing cyclin D1 and increasing p21
waf1. Cell lysates were collected 2 days after the gene transfection of
STAT1C in EC1 and EC109 (A). Time course experiments were performed, and the decrease in cyclin D1 expression was detectable as early as
6 hours after STAT1C transfection in EC1 cells (B). (C) Cell cycle analysis using flow cytometry revealed that STAT1C induced a significant increase
in the sub-G1 fraction in both cell lines, EC1 and EC109 (*p < 0.05). All experiments were performed in triplicate, and results from a representative
run are shown. (E.V.: empty vector).
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Figure 5 Inhibition of STAT1 activation by siRNA. By Western blot analysis, the protein level of STAT1 and phospho-STAT1 were dramatically decreased
in KYSE150 and KYSE510 treated with siRNA against STAT1. Cell lysates were collected 2 days after the siRNA transfection (A). The decrease in STAT1
expression after siRNA treatment was further supported by quantitative RT-PCR (***p < 0.0001) (B). In both KYSE150 and KYSE510, siRNA knockdown of
STAT1 induced a significant decrease in cell growth, assessed by trypan blue eclusion assay. The cell numbers were assessed on day 4 after siRNA
transfection. Triplicate experiments were performed and the results of a representative experiment are illustrated (*p < 0.05) (C). Transfection of STAT1 siRNA
into KYSE150 and KYSE510 cells led to a significant reduction in the number of colonies formed, as compared to cells transfected with scrambled siRNA.
Triplicate experiments were performed and the results of a representative experiment are shown (***p < 0.0001) (D). By western blots, transfection of STAT1
siRNA resulted in an appreciable increase in BCL-xL, BCL-2, cyclin D1 and a corresponding decrease in p21waf1. Cells treated with scrambled siRNA served
as the negative controls. Cell lysates were prepared two days after siRNA transfection (E). Cell cycle analysis using flow cytometry revealed that STAT1 siRNA
induced a significant decrease in the sub-G1 fraction in both cell lines, KYSE150 and KYSE510 (*p < 0.05). Results shown are representative of three
independent experiments (F).
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regulation of NF-κB transcriptional activity after STAT1C
transfection in both ESCC cells.
STAT1C transfection downregulates STAT3 expression and
activation
Since STAT1 and STAT3 are known to counteract each
other during their regulations of various cellular pro-
cesses [20,21], we asked if the modulation of STAT1
may have an impact on the expression and/or activation
of STAT3. As shown in Figure 7A, we found that the
expression levels for STAT3 and p-STAT3 were de-
creased 48 hours after STAT1C transfection into EC109Figure 6 STAT1C inhibits NF-κB signaling. Western blot results showed
STAT1C transfection in EC1 and EC109 cells (A). In the same experiment, nu
substantial decrease in nuclear p65 and phospho-p65 (B). (C) Using a NF-κ
significant down-regulation of the NF-κB transcription activity in ESCC cells
transfection. (*p < 0.05) (E.V.: empty vector).and EC1 cells. Correlating with these results, siRNA
knockdown of STAT1 substantially increased the expression
level of STAT3 and p-STAT3 in KYSE150 and KYSE510
(Figure 7A and B). We then assessed how STAT1C trans-
fection might affect the physical interaction between
STAT1 and STAT3 using co-immunoprecipitation. As
shown in Figure 7C (right panel), by Western blots, trans-
fection of STAT1C again resulted in 30-40% reduction in
the expression of STAT3. Co-immunoprecipitation studies
(left panel) showed that transfection of STAT1C substan-
tially increased the STAT3-STAT1 binding in both EC1
and EC109 cells. Considering that the total STAT3 protein
level was decreased after STAT1C expression, these co-a detectable down-regulation of total p65 and phospho-p65 after
clear/cytoplasmic fractionation studies showed that STAT1C induced a
B/luciferase reporter, we found that STAT1C gene transfection induce a
transfected with STAT1C cells were harvested 48 hours after the gene
Figure 7 STAT1C decreases the expression level of STAT3 and phospho-STAT3 and increase STAT1-STAT3 heterodimer formation.
Western blot studies showed that gene transfection of STAT1C induced an appreciable decrease in total STAT3 and phospho-STAT3 in EC1 and
EC109 cells. Cell lysates were harvested 48 hours after gene transfection (A). In contrast, both STAT3 and phospho-STAT3 were increased in
response to siRNA knockdown of STAT1 in KYSE150 and KYSE510 (B). Co-immunoprecipitation experiments revealed that gene transfection of
STAT1C into EC1 and EC109 induced a substantial increase in STAT1:STAT3 heterodimer; at the same time, the total STAT3 protein level was
decreased (C). Cell lysates were prepared 48 hours after gene transfection. (E.V.: empty vector).
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that the STAT3 homodimers are decreased upon STAT1C
transfection.Discussion
STAT1 has been reported to regulate cellular differentiation
and apoptosis through transcription-dependent as well as
transcription-independent mechanisms [22]. There is also
evidence that STAT1 carries tumor suppressor functions
[23-25]. Decreased or loss of STAT1 expression has been
observed in many cancer types such as breast cancer, mel-
anoma and leukemia [2,26-28]; transfection of STAT1 or
STAT1C into cancer cells can arrest their growth by indu-
cing apoptosis and cell-cycle arrest [1,9,29]. STAT1 appears
to exert its tumor suppressor functions via multiple mecha-
nisms, including downregulation of caspases, Fas, FasL,
TRAIL and p21waf1 [22]. The apoptosis-inducing function
of STAT1 also has been linked to its inhibition of IFN-γ sig-
naling and the subsequent downregulation of several pro-
apoptotic proteins including Bak and Bax [2]. Despite the
fact that the tumor suppressor function of STAT1 isincreasingly recognized, the significance of STAT1 in ESCC
has not been clearly defined.
One of the key findings of this study is that the absence
of STAT1 expression in ESCC significantly correlates with
a worse clinical outcome. Of note, we would like to ac-
knowledge that this observation was based on a compari-
son between 8 STAT1-negative and 66 STAT1-strong/
weak tumors. This highly skewed pattern may have intro-
duced some biases; thus, larger studies using other patient
cohorts are needed to confirm this finding. Nonetheless,
we do believe that STAT1 holds prognostic value, since
we found prognostic significance when we compared
STAT1-weak/negative cases and STAT1-strong cases in
the cohort of poorly or intermediate-differentiated tumors
(Figure 1C). Furthermore, STAT1 expression was also
found to correlate with the depth of tumor invasion and
tumor size. In this regard, tumor size is one of the deter-
minants of the TNM clinical staging system for ESCC
patients [30,31]. To our knowledge, the prognostic signifi-
cance of STAT1 in ESCC has never been previously de-
scribed. Nevertheless, we are aware of a relatively small
number of published studies that had found prognostic
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gastric cancer and melanoma [26,32].
Correlating with our clinical observations, our in-vitro
studies have provided further support that STAT1 car-
ries tumor suppressor functions in ESCC. Specifically,
we found that transfection of STAT1C into ESCC in-
duced apoptosis and cell-cycle arrest, with the effect on
apoptosis being more pronounced than that on cell pro-
liferation (Figures 3 and 4). On the other hand, siRNA
knock-down of STAT1 in ESCC cells results in opposite
effects. In parallel to our findings, we have identified two
in-vitro studies in the literature that may have impli-
cated a role of STAT1 in the biology of ESCC [9,33]. In
one of these two studies, IFN-γ and EGF were found to
induce apoptosis in KYSE 70 and KYSE 590, two ESCC
cell lines [9]. However, while the apoptosis induced by
both cytokines was found to correlate with STAT1 acti-
vation, whether STAT1 activation is directly responsible
for the occurrence of apoptosis in these cells was not
clear. In this current study, the use of STAT1C and
STAT1 siRNA allowed us to pinpoint STAT1 as a key
mediator of the induction of apoptosis and cell-cycle ar-
rest in ESCC.
We attempted to delineate the mechanisms by which
STAT1 induces apoptosis in ESCC. We found that some
of the mechanisms are similar to those previously re-
ported for other cancer types [34]. Thus, gene transfec-
tion of STAT1C in fibrosarcoma cell lines was found to
induce caspase activation and caspase-dependent apop-
tosis [13]. As we found that STAT1C-induced apoptosis
in ESCC correlates with the down-regulation of several
pro-survival proteins such as BCL-2 and BCL-xL, previ-
ous studies also have shown that STAT1 can promote
apoptosis by down-regulating BCL-2 and BCL-xL in
multiple myelomas [29].
We also have found evidence that STAT1 can modu-
late the expression of G1 cell-cycle regulatory proteins
such as p21waf1 and cyclin D1 in ESCC. Upregulation of
cyclin D1 has been shown to shorten the G1 phase and
reported to link to the development and progression of
many types of cancer, such as breast cancer [35], gastric
cancer [36] and mantle cell lymphoma [37]. In ESCC,
cyclin D1 expression detectable by IHC is associated
with a worse prognosis [38,39]. Thus, down-regulation
of cyclin D1 induced by STAT1 may partly explain our
observation that high STAT1 expression in ESCC is as-
sociated with a better clinical outcome. As shown in
Figure 4B, our observation that the down-regulation of
cyclin D1 occurred as early as 6 hours after STAT1C
gene transfection suggests that this biochemical change
was a consequence of STAT1 up-regulation, rather than
a ‘by-product’ of apoptosis.
In various cancer cell types, STAT1 has been previ-
ously reported to be an important mediator for NF-κB,which is known to play a critical role in carcinogenesis
and chemoresistance in ESCC [40,41]. The NF-κB sig-
naling pathway was found to be constitutively activated
in many ESCC cell lines; down-regulation of p65 has
been shown to increase the sensitivity of ESCC cells to
chemotherapeutic drugs [17,18]. With this background,
we tested if STAT1 is functionally linked to NF-κB in
our experimental model. Our findings that modulation
of STAT1 expression changed the expression level of
phospho-p65, as well as the nuclear localization of p65/
phospho-p65, and these findings support the concept
that the STAT1 inhibits the growth of ESCC via its sup-
pression of NF-κB signaling. Similar results have been
described in cervical cancer, melanomas and fibrosarco-
mas [16,42-44].
STAT3, another member of the STAT family, has been
shown to exert opposing biological effects of STAT1
[20,21,45]. In contrast with STAT1, STAT3 promotes
survival, proliferation and motility of cancer cells, and
induces immune tolerance [46]. Some of these opposing
biological effects are likely related to the cross-talk be-
tween STAT1 and STAT3. For instance, it has been
shown that STAT3 can block the activation and function
of STAT1 in human monocytic cells [47]. STAT3-
knockout mouse embryonic fibroblasts exhibited pro-
longed IL-6-mediated STAT1 activation and induction
of IFN-γ-inducible genes [48]. In this study, we found
evidence that STAT1 interferes with STAT3 signaling in
ESCC cells using at least two mechanisms. First, STAT1
down-regulates STAT3 as well as phospho-STAT3. To
our knowledge, this is a novel finding. Second, co-
immunoprecipitation studies showed that STAT1C trans-
fection in ESCC cells substantially increased STAT1:
STAT3 heterodimer. Since the total STAT3 protein level
was decreased after STAT1C transfection, it is logical to
assume that STAT3:STAT3 homodimers were dramatic-
ally decreased at the same time. We believe that these
findings are linked to the tumor suppressive effects of
STAT1C in ESCC, as previous studies have shown that
the relative proportions of STAT1 homodimers, STAT3
homodimers and STAT1:STAT3 heterodimers dictate the
cell fate [21,49,50]. Based on the literature, other mecha-
nisms where STAT1 inhibits STAT3 signaling may also
exist. For instance, it has been shown that STAT1 can
compete with STAT3 for the common receptor docking
sites or target DNA sequences [2,20]. Of note, most of
these STAT1-mediated effects on STAT3 take place in the
cytoplasm, and this may correlate with our observation
that cytoplasmic STAT1, rather than nuclear STAT1, was
prognostically important.
The role of STAT1 as a tumor suppressor is not without
controversy. STAT1 overexpression has been demon-
strated in several types of human cancer [51-55]. Some re-
ports also have demonstrated that constitutive STAT1
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chemotherapy and radiation, and carries a worse clinical
outcome in patients with glioblastoma multiforme [56].
The possible explanations for these rather contradictory
findings may be related to the biological heterogeneity of
cancer and STAT1 may function as a tumor suppressor or
oncoprotein in a cell-type specific manner.
Conclusion
In conclusion, our findings suggest that STAT1 is a tumor
suppressor in ESCC. Loss of STAT1, which is frequent in
ESCC, contributes to the pathogenesis of these tumors.
We have provided evidence that STAT1 attenuates the
tumorigenicity of ESCC by inhibiting the STAT3 and NF-
κB signaling pathway, and therefore that activation of
STAT1 may be a useful approach to treat ESCC.
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